Marc Bonten1, James R Johnson2, Anita H J van den Biggelaar3, Leonidas Georgalis3, Jeroen Geurtsen4, Patricia Ibarra de Palacios5, Stefan Gravenstein6, Thomas Verstraeten3, Peter Hermans4, Jan T Poolman4. 1. Julius Center, UMC Utrecht, Utrecht University, Utrecht, The Netherlands. 2. Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. 3. P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium. 4. Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands. 5. Clinical Development, Janssen Vaccines, Bern, Switzerland. 6. Brown University and Providence Veterans Administration Hospital, Providence, Rhode Island, USA.
Abstract
BACKGROUND: Escherichia coli is the most common cause of bacteremia in high-income countries. To enable the development and implementation of effective prevention strategies, a better understanding of the current epidemiology of invasive E. coli infections is needed. METHODS: A systematic review of literature published between 1 January 2007 and 31 March 2018 on the burden and epidemiology of E. coli bacteremia in populations that include adults in high-income countries was conducted. Meta-analysis was performed for descriptive purposes. RESULTS: During the studied time interval, the estimated incidence rate of E. coli bacteremia was 48 per 100 000 person-years, but this increased considerably with age: rates per 100 000 person-years were >100 in 55-to-75-year-olds and >300 in 75-to-85-year-olds. Overall, E. coli accounted for 27% of documented bacteremia episodes: 18% if hospital acquired, 32% if community-onset healthcare associated, and 33% if community acquired. The estimated case fatality rate was 12%. Approximately 44% of episodes were community acquired, 27% community-onset healthcare associated, and 27% hospital acquired. Urinary tract infection (UTI) was the primary source for 53% of episodes. CONCLUSIONS: This systematic review confirms the substantial burden of E. coli bacteremia in older adults and justifies the implementation of community-level programs to prevent E. coli bacteremia and ideally UTI in this age group.
BACKGROUND:Escherichia coli is the most common cause of bacteremia in high-income countries. To enable the development and implementation of effective prevention strategies, a better understanding of the current epidemiology of invasive E. coli infections is needed. METHODS: A systematic review of literature published between 1 January 2007 and 31 March 2018 on the burden and epidemiology of E. coli bacteremia in populations that include adults in high-income countries was conducted. Meta-analysis was performed for descriptive purposes. RESULTS: During the studied time interval, the estimated incidence rate of E. coli bacteremia was 48 per 100 000 person-years, but this increased considerably with age: rates per 100 000 person-years were >100 in 55-to-75-year-olds and >300 in 75-to-85-year-olds. Overall, E. coli accounted for 27% of documented bacteremia episodes: 18% if hospital acquired, 32% if community-onset healthcare associated, and 33% if community acquired. The estimated case fatality rate was 12%. Approximately 44% of episodes were community acquired, 27% community-onset healthcare associated, and 27% hospital acquired. Urinary tract infection (UTI) was the primary source for 53% of episodes. CONCLUSIONS: This systematic review confirms the substantial burden of E. coli bacteremia in older adults and justifies the implementation of community-level programs to prevent E. coli bacteremia and ideally UTI in this age group.
Authors: Melissa C MacKinnon; Scott A McEwen; David L Pearl; Outi Lyytikäinen; Gunnar Jacobsson; Peter Collignon; Daniel B Gregson; Louis Valiquette; Kevin B Laupland Journal: Antimicrob Resist Infect Control Date: 2021-09-06 Impact factor: 4.887
Authors: Laurent Chorro; Zhenghui Li; Ling Chu; Suddham Singh; Jianxin Gu; Jin-Hwan Kim; Kaushik Dutta; Rosalind Pan; Srinivas Kodali; Duston Ndreu; Axay Patel; Julio C Hawkins; Chris Ponce; Natalie Silmon de Monerri; David Keeney; Arthur Illenberger; C Hal Jones; Lubomira Andrew; Jason Lotvin; A Krishna Prasad; Isis Kanevsky; Kathrin U Jansen; Annaliesa S Anderson; Robert G K Donald Journal: Infect Immun Date: 2022-03-21 Impact factor: 3.609
Authors: Elita Jauneikaite; Kate Honeyford; Oliver Blandy; Mia Mosavie; Max Pearson; Farzan A Ramzan; Matthew J Ellington; Julian Parkhill; Céire E Costelloe; Neil Woodford; Shiranee Sriskandan Journal: J Antimicrob Chemother Date: 2022-05-29 Impact factor: 5.758
Authors: Melissa C MacKinnon; Scott A McEwen; David L Pearl; Outi Lyytikäinen; Gunnar Jacobsson; Peter Collignon; Daniel B Gregson; Louis Valiquette; Kevin B Laupland Journal: BMC Infect Dis Date: 2021-06-25 Impact factor: 3.090
Authors: Mohammed Almogbel; Ahmed Altheban; Mohammed Alenezi; Khalid Al-Motair; Godfred A Menezes; Mohammed Elabbasy; Sahar Hammam; John P Hays; Mushtaq A Khan Journal: Infect Drug Resist Date: 2021-07-23 Impact factor: 4.003